Keyphrases
Altered Pharmacokinetics
7%
Antifungal Drugs
23%
Augmented Renal Clearance
7%
Aurès
7%
Azole Antifungals
7%
Azole-resistant Aspergillus Fumigatus
7%
Candida Auris
7%
Candida Species
7%
Changing Epidemiology
7%
Clinical Model
7%
Clinical Outcomes
7%
Clinical Pharmacology
23%
Coccidioides Spp
7%
Comparative Effectiveness
7%
Current Therapeutics
7%
Dose Optimization
15%
Dosing Recommendations
7%
Drug Dosing
7%
Echinocandins
100%
Emerging Infections
7%
Emerging Pathogen
7%
Fluconazole
15%
Fungi
7%
Human Studies
15%
Infection Infection
7%
Invasive Aspergillosis
7%
Invasive Candidiasis
15%
Invasive Fungal Infection
7%
Isavuconazole
7%
Itraconazole
7%
Novel Antifungals
15%
Patient Demographics
7%
Pharmacodynamic Research
100%
Pharmacodynamic Study
30%
Pharmacodynamic Target
30%
Pharmacodynamics Target Attainment
7%
Pharmacokinetics-pharmacodynamics (PK-PD)
100%
Posaconazole
7%
Randomized Comparative Study
7%
Rare Fungal Infections
7%
Reduced Susceptibility
7%
Rezafungin
15%
Selection Optimization
7%
Special Patient Population
7%
Therapeutic Drug Monitoring
15%
Treatment Decisions
7%
Triazole
100%
Voriconazole
7%
Pharmacology, Toxicology and Pharmaceutical Science
Antifungal Agent
46%
Aspergillus fumigatus
7%
Candida
7%
Candida Auris
7%
Clinical Pharmacokinetics
23%
Coccidioides
7%
Echinocandin
100%
Fluconazole
15%
Human Study
15%
Infection
23%
Infectious Agent
7%
Invasive Aspergillosis
7%
Invasive Candidiasis
15%
Isavuconazole
7%
Itraconazole
7%
Mycosis
7%
Pharmacodynamics
100%
Pharmacokinetics
100%
Posaconazole
7%
Pyrrole
15%
Rezafungin
15%
Systemic Mycosis
7%
Therapeutic Drug Monitoring
15%
Triazole
7%
Triazole Derivative
100%
Voriconazole
7%